PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

被引:47
|
作者
Yvorel, Violaine [1 ]
Patoir, Arnaud [2 ]
Casteillo, Francois [1 ]
Tissot, Claire [3 ]
Fournel, Pierre [4 ]
Stachowicz, Marie-Laure [1 ]
Karpathiou, Georgia [1 ]
Tiffet, Olivier [2 ]
Peoc'h, Michel [1 ]
Forest, Fabien [1 ]
机构
[1] Univ Hosp St Etienne, North Hosp, Dept Pathol, St Etienne, France
[2] Univ Hosp St Etienne, North Hosp, Dept Thorac Surg, St Etienne, France
[3] Univ Hosp St Etienne, North Hosp, Dept Pneumol, St Etienne, France
[4] Lucien Neuwirth Canc Inst, Dept Oncol, St Priest En Jarez, France
来源
PLOS ONE | 2017年 / 12卷 / 07期
关键词
DEATH LIGAND-1 PD-L1; SHOW HIGH-LEVELS; CANCER;
D O I
10.1371/journal.pone.0180346
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Lung sarcomatoid carcinoma of the lung is a rare tumor with a poor prognosis. More than 90% of them are pleomorphic, spindle cell and giant cell carcinoma (PSCGCC). This rare subtype of lung cancer is thought to be more resistant to chemotherapy, and a small subset of them seems to exhibit targetable mutations. Immunotherapy against PD1/PDL-1 is a new emerging treatment, and might be of interest in PSGSCC because they frequently express PD-L1. The aim of our work is to evaluate PD1 and PDL-1 expression in a surgical series of lung PSCGCC and their relationship with morphological and immunohistochemical parameters and prognosis. Thirty-six patients who underwent surgical resection of a PSGSCC were included. PD-L1 (E1L3N) expression on tumor cells and PD1 (NAT105) expression by tumor infiltrating lymphocytes (TILs) were performed by immunohistochemistry. Results were compared to immunohistochemistry tests of TTF1, Napsin A, p40 and to molecular study of EGFR, KRAS, BRAF and HER2. Seventy-five % of PSCGCC were considered as positive for PD-L1. PD-L1 expression in PSGSCC is associated with TTF-1 and/or Napsin A expression (47.2%, p = 0.039). Few p40 positive PSCGCC expressed PD-L1 (8.3%, p = 0.013). PD1 expression was not related to TTF-1 and/or Napsin A expression (p = 0.47), p40 expression (p = 0.68) or survival (p = 0.14). PD-L1 or PD1 expression were not related to the age, gender, pT, pN, stage, visceral pleura invasion, histopathological subtype, the presence of giant cell component, the predominance of sarcomatoid component, and the presence of EGFR or BRAF or HER2 or PIK3CA mutation (p> 0.05). PD-L1 expression was correlated with a worse overall survival in PSCGCC (p = 0.045). PD-L1 expression is frequent in PSCGCC and might be associated with the expression of adenocarcinoma markers (TTF-1, Napsin A) or the lack of expression of squamous cell carcinoma marker (p40).
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Expression and correlation of PD-L1 and HER2 in oesophageal squamous cell carcinoma
    Rong, Lulu
    Zhao, Hongying
    Li, Yunlong
    Jin, Mulan
    Lu, Jun
    JOURNAL OF CLINICAL PATHOLOGY, 2024, 77 (04) : 233 - 238
  • [42] Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC)
    Abbas, M.
    Steffens, S.
    Bellut, M.
    Eggers, H.
    Grosshennig, A.
    Becker, J. U.
    Wegener, G.
    Schrader, A. J.
    Gruenwald, V.
    Ivanyi, P.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [43] Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1
    Luo, Haiming
    Yang, Changwen
    Kuang, Dong
    Shi, Sixiang
    Chan, Annie W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (08) : 2735 - 2745
  • [44] PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials
    Jin, Cao
    Hacking, Sean
    Liang, Sharon
    Nasim, Mansoor
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2020, 28 (01) : 31 - 37
  • [45] Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC)
    Bialek, Joanna
    Yankulov, Stefan
    Kawan, Felix
    Fornara, Paolo
    Theil, Gerit
    BIOMEDICINES, 2022, 10 (12)
  • [46] Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study
    Greeshma, L. R.
    Joseph, Anna P.
    Sivakumar, T. T.
    Pillai, Varun Raghavan
    Vijayakumar, Gopikrishnan
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [47] RICTOR amplification is associated with Rictor membrane staining and does not correlate with PD-L1 expression in lung squamous cell carcinoma
    Krencz, Ildiko
    Sztankovics, Daniel
    Sebestyen, Anna
    Papay, Judit
    Danko, Titanilla
    Moldvai, Dorottya
    Lutz, Elmar
    Khoor, Andras
    PATHOLOGY & ONCOLOGY RESEARCH, 2024, 30
  • [48] Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy
    Takada, Kazuki
    Kohashi, Kenichi
    Shimokawa, Mototsugu
    Haro, Akira
    Osoegawa, Atsushi
    Tagawa, Tetsuzo
    Seto, Takashi
    Oda, Yoshinao
    Maehara, Yoshihiko
    LUNG CANCER, 2019, 128 : 26 - 32
  • [49] Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma
    Ito, Atsushi
    Tarukawa, Tomohito
    Suzuki, Yuta
    Sakaguchi, Tadashi
    Ito, Kentaro
    Fujiwara, Kentaro
    Nishii, Yoichi
    Taguchi, Osamu
    Yasui, Hiroki
    Takao, Motoshi
    Hataji, Osamu
    ANTICANCER RESEARCH, 2023, 43 (11) : 5197 - 5204
  • [50] Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Callea, Marcella
    Albiges, Laurence
    Gupta, Mamta
    Cheng, Su-Chun
    Genega, Elizabeth M.
    Fay, Andre P.
    Song, Jiaxi
    Carvo, Ingrid
    Bhatt, Rupal S.
    Atkins, Michael B.
    Hodi, F. Stephen
    Choueiri, Toni K.
    McDermott, David F.
    Freeman, Gordon J.
    Signoretti, Sabina
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1158 - 1164